IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading pet healthcare company, on Monday reported an increase in revenue and net income for the second quarter of fiscal 2025.
- Second-quarter revenue increased to $1.11 billion from $1.0 billion in the prior-year quarter, up 11%
- On an organic basis, revenue grew 9%, supported by CAG diagnostics recurring revenue growth of 9% as reported and 7% organic
- Net income was $294.0 million in Q2 2025, compared to $203.3 million in the prior-year quarter
- Earnings, on a per-share basis, climbed 49% year-over-year to $3.63 in Q2; EPS grew 17% on a comparable basis
- The management raised its full-year revenue guidance to $4,205-4,280 million, an increase of $90 million or around 2% at midpoint
- The guidance for full-year reported revenue growth is 7.7-9.7%; CAG diagnostics recurring revenue growth is expected to be 6.5-8.7%
- It expects full-year earnings to be in the range of $12.40 per share to $12.76 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key metrics from Kroger’s (KR) Q3 2025 earnings results
The Kroger Co. (NYSE: KR) reported its third quarter 2025 earnings results today. Total company sales rose to $33.9 billion from $33.6 billion in the same period last year. Identical
Dollar General (DG) Q3 2025 Earnings: Key financials and quarterly highlights
Dollar General Corporation (NYSE: DG) reported its third quarter 2025 earnings results today. Net sales increased 4.6% year-over-year to $10.65 billion. Same-store sales increased 2.5%. Net income was $282.7 million, or
HRL Earnings: All you need to know about Hormel Foods’ Q4 2025 earnings results
Hormel Foods Corporation (NYSE: HRL) reported its fourth quarter 2025 earnings results today. Net sales increased 1.5% year-over-year to $3.18 billion. Organic sales were up 2%. Net loss attributable to Hormel
